Coherus BioSciences Inc. (NASDAQ:CHRS)’s traded shares stood at 2.04 million during the last session, with the company’s beta value hitting 0.95. At the close of trading, the stock’s price was $6.08, to imply a decrease of -4.55% or -$0.29 in intraday trading. The CHRS share’s 52-week high remains $14.11, putting it -132.07% down since that peak but still an impressive 8.22% since price per share fell to its 52-week low of $5.58. The company has a valuation of $497.65M, with an average of 1.46 million shares in intraday trading volume over the past 10 days and average of 1.27 million shares over the past 3 months.
Coherus BioSciences Inc. (NASDAQ:CHRS) trade information
After registering a -4.55% downside in the last session, Coherus BioSciences Inc. (CHRS) has traded red over the past five days. The stock hit a weekly high of 6.75 this Friday, 03/17/23, dropping -4.55% in its intraday price action. The 5-day price performance for the stock is 0.16%, and -22.94% over 30 days. With these gigs, the year-to-date price performance is -23.23%. Short interest in Coherus BioSciences Inc. (NASDAQ:CHRS) saw shorts transact 9.54 million shares and set a 7.35 days time to cover.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Analysts on Wall Street suggest a consensus price target of $17.43, implying an increase of 65.12% to the stock’s current value. The extremes give us $9.00 and $30.00 for target low and target high price respectively. As such, CHRS has been trading -393.42% off suggested target high and -48.03% from its likely low.
Coherus BioSciences Inc. (CHRS) estimates and forecasts
Looking at statistics comparing Coherus BioSciences Inc. share performance against respective industry, we note that the company has outperformed competitors. Coherus BioSciences Inc. (CHRS) shares are -42.26% down over the last 6 months, with its year-to-date growth rate higher than industry average at 104.97% against 9.60%. Revenue is forecast to shrink -82.60% this quarter before jumping 52.00% for the next one. The rating firms project that company’s revenue will shrink -33.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is $47.68 million. Meanwhile, for the quarter ending Mar 2023, a total of 5 analyst(s) estimate revenue growth to $62.1 million.Earnings reports from the last fiscal year show that sales brought in $73.37 million and $60.12 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -35.00% before jumping 3.30% in the following quarter.
Coherus BioSciences Inc. has its next earnings report out between May 03 and May 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Coherus BioSciences Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Coherus BioSciences Inc. (NASDAQ:CHRS)’s Major holders
Coherus BioSciences Inc. insiders hold 2.08% of total outstanding shares, with institutional holders owning 107.83% of the shares at 110.11% float percentage. In total, 107.83% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 12.98 million shares (or 16.69% of shares), all amounting to roughly $124.78 million.
The next major institution holding the largest number of shares is Temasek Holdings (Private) Limited with 7.38 million shares, or about 9.49% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $70.93 million.
We also have iShares Core S&P Smallcap ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the Coherus BioSciences Inc. (CHRS) shares. Going by data provided on Dec 30, 2022, iShares Core S&P Smallcap ETF holds roughly 4.82 million shares. This is just over 6.19% of the total shares, with a market valuation of $38.15 million. Data from the same date shows that the other fund manager holds a little less at 4.49 million, or 5.78% of the shares, all valued at about 35.59 million.